Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Outline
- Conventional pharmaceutical dosage forms (1)
- Conventional pharmaceutical dosage forms (2)
- Conventional pharmaceutical dosage forms (3)
- Strategies to improve drug bioavailability
- Nanosystems (1)
- Nanosystems (2)
- Nanosystems (3)
- Liposomes (1)
- Liposomes (2)
- Micelles (1)
- Micelles (2)
- Nanoemulsions (1)
- Nanoemulsions (2)
- Microemulsions (1)
- Microemulsions (2)
- Nanoparticles
- Polymeric nanoparticles (1)
- Polymeric nanoparticles (2)
- Lipid nanoparticles (1)
- Lipid nanoparticles (2)
- Lipid nanoparticles (3)
- Protein nanoparticles (1)
- Magnetic nanoparticles (1)
- Magnetic nanoparticles (2)
- Dendrimers
- Nanosystem limitations
- Conclusion
- References
- Thank you!
Topics Covered
- Conventional pharmaceutical dosage forms
- Strategies to improve drug bioavailability
- Liposomes
- Micelles
- Nanoemulsions
- Microemulsions
- Nanoparticles
- Polymeric and lipidic nanoparticles
- Dendrimers
- Limitations of nanosystems
Links
Series:
Categories:
External Links
Talk Citation
Silva, A.C. (2019, October 31). Need for drug delivery systems 1 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 10, 2024, from https://doi.org/10.69645/AAKR8898.Export Citation (RIS)
Publication History
Financial Disclosures
- There are no commercial/financial matters to disclose.
Need for drug delivery systems 1
Published on October 31, 2019
16 min
Other Talks in the Series: Drug Delivery
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is Ana Catarina Silva and
I'm an Assistant Professor of University Fernando Pessoa,
an invited Professor at the Faculty of Pharmacy from Porto, Portugal.
This is the first part of the talk on the "Need for Drug Delivery Systems" and
the second part will be delivered by my colleague Professor Joao Nuno Moreira.
0:23
I will start my presentation with an explanation about the general limitations of
the conventional pharmaceutical dosage forms and some of
the strategies used for improved drug bioavailability.
Afterwards, I'll provide an overview about the drug delivery systems and in particular,
the most studied nanosystems.
Finally, I'll end with some concluding remarks.
0:48
Among the general limitations of conventional pharmaceutical dosage forms are;
the fast drug elimination from the body which leads to unfavorable pharmacokinetics,
the need to perform repeated administration to achieve
constant drug plasma concentration that can originate problems of patient compliance.
The lack on the drug selectivity for target tissues that is responsible for
adverse and sub-therapeutic effects and the occurrence of
drug degradation and toxicity in the body that can originate in tissue damage.
All these limitations originate bioavailability problems.
1:30
Other limitations of the conventional pharmaceutical dosage forms are related to
the frequent synthesis of new drug molecules that belong to the BCS classes II and IV,
presenting lipophilic characteristics and
low solubility which may precipitate in aqueous media
and also to the BCS class III that have
high solubility and poor intestinal permeability.
These drugs present difficulties of formulation and therefore bioavailability problems.